Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorphen...
Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies
About this item
Full title
Author / Creator
Valerio-Pascua, Fernando , Baires, Fernando , Sekhon, Anupamjeet Kaur , Tesch, Mari L. , Pineda, Estela Jackeline , Rizvi, Syed A. A. , Singh, Jarmanjeet , Cortes-Bandy, David Abraham , Madril, Amy C. , Radwanski, Jana , Lewis, Anita S. , Sierra-Hoffman, Miguel , Stevens, Mark L. and Rahaghi, Franck F.
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
The World Health Organization (WHO) declared the end of the COVID-19 (SARS-CoV-2) global public health emergency on May 5, 2023, but its long-term consequences have still been haunting the global population. Post-acute sequelae of COVID-19 (PASC) and long-term COVID-19 are serious concerns and present with various symptoms. Intranasal chlorpheniram...
Alternative Titles
Full title
Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1b1738b9e2ce4af088219ed5969dcd17
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1b1738b9e2ce4af088219ed5969dcd17
Other Identifiers
ISSN
1471-2334
E-ISSN
1471-2334
DOI
10.1186/s12879-024-10211-8
